These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 28246042)

  • 1. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
    Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
    Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
    Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
    Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Evaluation of Novel Tyrosine-Based DNA Gyrase B Inhibitors.
    Cotman AE; Trampuž M; Brvar M; Kikelj D; Ilaš J; Peterlin-Mašič L; Montalvão S; Tammela P; Frlan R
    Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28621824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
    Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
    Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
    Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
    Tomašič T; Katsamakas S; Hodnik Ž; Ilaš J; Brvar M; Solmajer T; Montalvão S; Tammela P; Banjanac M; Ergović G; Anderluh M; Peterlin Mašič L; Kikelj D
    J Med Chem; 2015 Jul; 58(14):5501-21. PubMed ID: 26098163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
    Tari LW; Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Nix J; Finn J
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1529-36. PubMed ID: 23352267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
    Gjorgjieva M; Tomašič T; Barančokova M; Katsamakas S; Ilaš J; Tammela P; Peterlin Mašič L; Kikelj D
    J Med Chem; 2016 Oct; 59(19):8941-8954. PubMed ID: 27541007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
    Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
    Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.
    Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N
    ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in the discovery and development of DNA gyrase B inhibitors.
    Barančoková M; Kikelj D; Ilaš J
    Future Med Chem; 2018 May; 10(10):1207-1227. PubMed ID: 29787300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
    Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
    PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
    Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity.
    Frejat FOA; Cao Y; Wang L; Zhai H; Abdelazeem AH; Gomaa HAM; Youssif BGM; Wu C
    Arch Pharm (Weinheim); 2022 Jul; 355(7):e2100516. PubMed ID: 35363388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
    Hossion AM; Zamami Y; Kandahary RK; Tsuchiya T; Ogawa W; Iwado A; Sasaki K
    J Med Chem; 2011 Jun; 54(11):3686-703. PubMed ID: 21534606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
    Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N
    Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
    Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
    J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-generation 4,5,6,7-tetrahydrobenzo[
    Lamut A; Skok Ž; Barančoková M; Gutierrez LJ; Cruz CD; Tammela P; Draskovits G; Szili PÉ; Nyerges Á; Pál C; Molek P; Bratkovič T; Ilaš J; Zidar N; Zega A; Enriz RD; Kikelj D; Tomašič T
    Future Med Chem; 2020 Feb; 12(4):277-297. PubMed ID: 32043377
    [No Abstract]   [Full Text] [Related]  

  • 20. DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
    East SP; White CB; Barker O; Barker S; Bennett J; Brown D; Boyd EA; Brennan C; Chowdhury C; Collins I; Convers-Reignier E; Dymock BW; Fletcher R; Haydon DJ; Gardiner M; Hatcher S; Ingram P; Lancett P; Mortenson P; Papadopoulos K; Smee C; Thomaides-Brears HB; Tye H; Workman J; Czaplewski LG
    Bioorg Med Chem Lett; 2009 Feb; 19(3):894-9. PubMed ID: 19095445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.